Source: Annual Congress 2010 - Pulmonary circulation II
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Stanziola, M. D‘Alto, E. Carpentieri, P. Argiento, C. Russo, E. Romeo, A. Molino, R. Calabrò, M. Sofia (Naples, Italy). Endothelin receptor antagonist (ETRA) bosentan (B) in patients with severe pulmonary hypertension (PH) associated with pulmonary disease. Eur Respir J 2010; 36: Suppl. 54, 1123

Member's Comments

No comment yet.

Related content which might interest you: Longterm treatment effects of pulmonary hypertantion (PH) in idiopathic pulmonary fibrosis (IPF) patients by endothelin receptor blockade (Bosentan) Source: Eur Respir J 2007; 30: Suppl. 51, 120s Year: 2007 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013 The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension (PAH) associated with congenital heart defects (CHD) Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Survival with first-line bosentan in patients with primary pulmonary hypertension Source: Eur Respir J 2005; 25: 244-249 Year: 2005 Fractalkine and its receptor (CX3CR1) in primary pulmonary hypertension (PPH) Source: Eur Respir J 2001; 18: Suppl. 33, 2s Year: 2001 Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008 Distinct effects of the endothelin receptor antagonists PD 142893 (ET-A/B), BQ 788 (ET-B) and N-Ac-Trp-ET 1 Frg. 16-21 (ET-A) on oxidative stress-induced pulmonary hypertension in isolated rabbit lungs Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Endothelin: setting the scene in PAH Source: Eur Respir Rev 2008; 17: 3-7 Year: 2007 Bosentan therapy for portopulmonary hypertension Source: Eur Respir J 2005; 25: 502-508 Year: 2005 Sustained efficacy with the selective endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 204s Year: 2005 Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004 A possible role of plasma serotonin (5-HT) and histamin level in pulmonary hypertension (PH) in patients with interstitial lung diseases (ILD) Source: Eur Respir J 2001; 18: Suppl. 33, 416s Year: 2001 Blocking endothelin: breaking new ground Source: Eur Respir Rev 2008; 17: 24-29 Year: 2007 Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007 Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007